<DOC>
	<DOCNO>NCT01952574</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , parallel-group , multi-center study follow open-label phase . To evaluate effect AMG 334 compare placebo change baseline monthly migraine day</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety AMG 334 Migraine Prevention</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , parallel-group , multi-center study follow open-label phase . Adults one-year history episodic migraine receive migraine prophylaxis medication randomize one three AMG 334 treatment group placebo treatment group .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History migraine than12 month prior screen Migraine frequency : ≥ 4 ≤ 14 migraine day per month 3 month prior screen baseline phase Headache frequency : &lt; 15 headache day per month ( &gt; 50 % headache day migraine day ) 3 month prior screen baseline phase Demonstrated least 80 % compliance eDiary baseline phase Older 50 year age migraine onset History cluster headache basilar hemiplegic migraine headache Unable differentiate migraine headache Failed &gt; 2 medication category due lack efficacy prophylactic treatment migraine adequate therapeutic trial Used prohibit migraine prophylactic medication , device procedure within 2 month prior start baseline phase Overuse acute migraine medication month 3 month prior screen screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>migraine , headache , prevention , prophylaxis</keyword>
</DOC>